Ligne de temps
![](https://research.pasteur.fr/wp-content/uploads/2015/05/member-150x150.png)
Nicolas Escriou
Chercheur(euse) Permanent(e)
02 avr. 2024
publication
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model.
Lire plus01 avr. 2023
publication
Development and comparative evaluation of SARS-CoV-2 S-RBD and N based ELISA tests in various African endemic settings
Lire plus01 janv. 2022
publication
Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.
Lire plus21 mai 2021
publication
Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance.
Lire plus01 janv. 2021
publication
High seroprevalence but short-lived immune response to SARS-CoV-2 infection in Paris.
Lire plus16 déc. 2020
publication
Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.
Lire plus02 sept. 2020
publication
A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations
Lire plus10 avr. 2020
04 juil. 2015